慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版)

2021-01-28 中华医学会血液学分会白血病淋巴瘤学组 中华血液学杂志.2021.42(1):5-9.

慢性粒-单核细胞白血病(Chronic myelomonocytic leukemia, CMML)是最常见的骨髓增生异常综合征/骨髓增殖性肿瘤(MDS/MPN),年发病率为(3~4)/10

中文标题:

慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版)

发布日期:

2021-01-28

简要介绍:

慢性粒-单核细胞白血病(Chronic myelomonocytic leukemia, CMML)是最常见的骨髓增生异常综合征/骨髓增殖性肿瘤(MDS/MPN),年发病率为(3~4)/10 万。近年,随着诊断技术的进步,特别是二代测序(NGS)在临床的应用,更新了CMML的诊断和分型诊断标准和预后危度分组标准。为了规范我国CMML的诊断和治疗,中华医学会血液学分会白血病淋巴瘤学组制定本指南。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=c83931c00208326e, title=慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版), enTitle=, guiderFrom=中华血液学杂志.2021.42(1):5-9., authorId=0, author=, summary=慢性粒-单核细胞白血病(Chronic myelomonocytic leukemia, CMML)是最常见的骨髓增生异常综合征/骨髓增殖性肿瘤(MDS/MPN),年发病率为(3~4)/10, cover=https://img.medsci.cn/2021420/1618929241495_2020535.jpg, journalId=0, articlesId=null, associationId=1285, associationName=中华医学会血液学分会白血病淋巴瘤学组, associationIntro=, copyright=0, guiderPublishedTime=Thu Jan 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>慢性粒-单核细胞白血病(Chronic myelomonocytic&nbsp;leukemia, CMML)是最常见的骨髓增生异常综合征/骨髓增殖性肿瘤(MDS/MPN),年发病率为(3~4)/10 万。近年,随着诊断技术的进步,特别是二代测序(NGS)在临床的应用,更新了CMML的诊断和分型诊断标准和预后危度分组标准。为了规范我国CMML的诊断和治疗,中华医学会血液学分会白血病淋巴瘤学组制定本指南。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=809, tagName=白血病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20369, categoryName=向日葵, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=809, guiderKeyword=白血病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8379, appHits=706, showAppHits=0, pcHits=1786, showPcHits=7673, likes=13, shares=71, comments=37, approvalStatus=1, publishedTime=Tue Apr 20 23:14:38 CST 2021, publishedTimeString=2021-01-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Apr 20 22:34:09 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:05:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版).pdf)])
慢性粒-单核细胞白血病诊断与治疗中国指南(2021年版).pdf
下载请点击:
评论区 (32)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1206907, encodeId=a25e120690eef, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a48c2650358, createdName=623735962, createdTime=Tue Mar 29 15:02:06 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196608, encodeId=f2d7119660832, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=350a2649169, createdName=907077531, createdTime=Wed Feb 23 23:10:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192186, encodeId=79e5119218681, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:46:25 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192185, encodeId=43961192185a4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:51 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192183, encodeId=fafc119218393, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:13 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-03-29 623735962

    干货

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1206907, encodeId=a25e120690eef, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a48c2650358, createdName=623735962, createdTime=Tue Mar 29 15:02:06 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196608, encodeId=f2d7119660832, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=350a2649169, createdName=907077531, createdTime=Wed Feb 23 23:10:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192186, encodeId=79e5119218681, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:46:25 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192185, encodeId=43961192185a4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:51 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192183, encodeId=fafc119218393, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:13 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-23 907077531

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1206907, encodeId=a25e120690eef, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a48c2650358, createdName=623735962, createdTime=Tue Mar 29 15:02:06 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196608, encodeId=f2d7119660832, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=350a2649169, createdName=907077531, createdTime=Wed Feb 23 23:10:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192186, encodeId=79e5119218681, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:46:25 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192185, encodeId=43961192185a4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:51 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192183, encodeId=fafc119218393, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:13 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-11 ms8000000360418948

    非常感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1206907, encodeId=a25e120690eef, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a48c2650358, createdName=623735962, createdTime=Tue Mar 29 15:02:06 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196608, encodeId=f2d7119660832, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=350a2649169, createdName=907077531, createdTime=Wed Feb 23 23:10:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192186, encodeId=79e5119218681, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:46:25 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192185, encodeId=43961192185a4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:51 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192183, encodeId=fafc119218393, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:13 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-11 ms8000000360418948

    非常感谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1206907, encodeId=a25e120690eef, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a48c2650358, createdName=623735962, createdTime=Tue Mar 29 15:02:06 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196608, encodeId=f2d7119660832, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=350a2649169, createdName=907077531, createdTime=Wed Feb 23 23:10:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192186, encodeId=79e5119218681, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:46:25 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192185, encodeId=43961192185a4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:51 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192183, encodeId=fafc119218393, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db5448514, createdName=ms8000000360418948, createdTime=Fri Feb 11 08:43:13 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-11 ms8000000360418948

    谢谢

    0

拓展阅读

2009 ELN 成人急性髓系白血病的诊断和治疗

欧洲白血病网(ELN,European LeukmiaNet) · 2009-10-30

成人急性髓系白血病(AML)诊断、治疗及随访的最低临床建议(2010)

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-01-01

中国慢性淋巴细胞白血病诊断与治疗专家共识(2010)

中华医学会血液学分会(CMA,CHINESE MEDICAL ASSOCIATION) · 2010-02-01

2010 慢性髓性白血病治疗专家共识

中华医学会血液学分会(CMA,CHINESE MEDICAL ASSOCIATION) · 2010-03-01

急性髓系白血病(2010)

美国癌症学会(ACS,American Cancer Society) · 2010-10-12

中国慢性髓系白血病诊断与治疗指南(2011年版)

中华医学会血液学分会(CMA,CHINESE MEDICAL ASSOCIATION) · 2011-06-01